Valuation : Abivax

Market Cap 8.74B 10.15B 8.28B 7.5B 14.08B 969B 14.15B 98.31B 37.81B 493B 38.11B 37.27B 1,558B P/E 2026 *
-28.3x
P/E 2027 * -33.3x
Enterprise Value 7.64B 8.87B 7.24B 6.56B 12.31B 848B 12.37B 85.96B 33.06B 431B 33.32B 32.59B 1,363B EV / Sales 2026 *
109x
EV / Sales 2027 * 97.9x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+1.00%
1 week+3.79%
Current month+3.84%
1 month-7.91%
3 months+18.97%
6 months+5.19%
Current year-15.86%
1 week 97.1
Extreme 97.1
105.1
1 month 95
Extreme 95
111.1
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.9
Extreme 3.9
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+1.00%+3.79%+41.28%+505.86% 10.17B
-0.71%-6.35%-4.87%+9.03% 46.05B
-0.10%-3.44%+338.56%+516.95% 43.59B
+1.46%-2.21%+37.32%+21.61% 42.35B
+1.51%-3.09%+3.43%+65.93% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+1.18%-2.78% - - 17.16B
+1.43%+0.31%+19.19%+112.31% 16.28B
-0.31%-2.78%+10.47%+30.49% 14.32B
+1.30%-3.85%+73.66%+38.93% 13.03B
Average +0.43%-4.16%+58.81%+148.85% 27.4B
Weighted average by Cap. +0.22%-4.87%+71.70%+138.51%

Financials

2026 *2027 *
Net sales 70.18M 81.45M 66.45M 60.23M 113M 7.78B 114M 789M 303M 3.96B 306M 299M 12.51B 79.52M 92.29M 75.3M 68.25M 128M 8.82B 129M 894M 344M 4.49B 347M 339M 14.17B
Net income -265M -308M -251M -228M -427M -29.4B -429M -2.98B -1.15B -14.96B -1.16B -1.13B -47.26B -231M -268M -218M -198M -372M -25.58B -373M -2.59B -998M -13.02B -1.01B -984M -41.13B
Net Debt -1.1B -1.27B -1.04B -942M -1.77B -122B -1.78B -12.35B -4.75B -61.94B -4.79B -4.68B -196B -956M -1.11B -905M -821M -1.54B -106B -1.55B -10.75B -4.13B -53.94B -4.17B -4.08B -170B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-11 101.30 +1.00% 92,586
26-09-10 €100.30 -0.89% 92,399
26-09-09 €101.20 +0.20% 165,097
26-09-08 €101.00 +3.11% 120,091
26-09-07 €97.95 +0.36% 88,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
100.30EUR
Average target price
137.98EUR
Spread / Average Target
+37.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!